ZA201702385B - Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states - Google Patents

Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states

Info

Publication number
ZA201702385B
ZA201702385B ZA2017/02385A ZA201702385A ZA201702385B ZA 201702385 B ZA201702385 B ZA 201702385B ZA 2017/02385 A ZA2017/02385 A ZA 2017/02385A ZA 201702385 A ZA201702385 A ZA 201702385A ZA 201702385 B ZA201702385 B ZA 201702385B
Authority
ZA
South Africa
Prior art keywords
micellizing
self
treatment
acid ester
disease states
Prior art date
Application number
ZA2017/02385A
Inventor
D Sancilio Frederick
Thorsteinsson Thorsteinn
DANIEL-ARCHIBALD Glynis
Lopez-Toledano Miguel
Abd Almalik Ahmed Mohammed Daak Ahmed
Original Assignee
Sancilio And Company Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54347886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201702385(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sancilio And Company Inc filed Critical Sancilio And Company Inc
Publication of ZA201702385B publication Critical patent/ZA201702385B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
ZA2017/02385A 2014-10-10 2017-04-04 Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states ZA201702385B (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462062652P 2014-10-10 2014-10-10
US201462062634P 2014-10-10 2014-10-10
US201462062651P 2014-10-10 2014-10-10
US201462062646P 2014-10-10 2014-10-10
US201462062643P 2014-10-10 2014-10-10
US201462062638P 2014-10-10 2014-10-10
PCT/US2015/054933 WO2016057915A1 (en) 2014-10-10 2015-10-09 Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states

Publications (1)

Publication Number Publication Date
ZA201702385B true ZA201702385B (en) 2020-12-23

Family

ID=54347886

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2017/02385A ZA201702385B (en) 2014-10-10 2017-04-04 Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states

Country Status (8)

Country Link
EP (1) EP3212236A1 (en)
BR (1) BR112017007428A2 (en)
CA (1) CA2963952C (en)
CL (1) CL2017000867A1 (en)
MA (1) MA40846A (en)
MX (2) MX2017004324A (en)
WO (1) WO2016057915A1 (en)
ZA (1) ZA201702385B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106692973A (en) * 2015-11-13 2017-05-24 深圳君圣泰生物技术有限公司 Pharmaceutical compositions and applications thereof, and pharmaceutical preparation
AU2016406709C1 (en) * 2016-05-10 2023-04-27 Shenzhen Hightide Biopharmaceutical., Ltd. Composition, and application and pharmaceutical preparation thereof
WO2018027278A1 (en) * 2016-08-12 2018-02-15 Pharmako Biotechnologies Pty Limited Omega-3 compositions and methods relating thereto
FR3092968B1 (en) * 2019-02-22 2021-05-21 Microphyt DIETARY SUPPLEMENT
IT201900007202A1 (en) * 2019-05-24 2020-11-24 Pavia Farm S R L COMPOSITION BASED ON LIPOSOLUBLE VITAMINS WITH HIGH ENTERIC ABSORPTION
MX2022001238A (en) 2019-08-13 2022-07-13 Team Foods Colombia Sa Lipid composition comprising antioxidants and natural polyphenols as a non-pharmacological alternative for the treatment and prevention of non-alcoholic fatty liver disease (nafld).
CN115737555B (en) * 2022-05-20 2024-06-21 深圳海王医药科技研究院有限公司 Cepharanthine self-microemulsion composition, preparation and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5313343B2 (en) * 2009-05-22 2013-10-09 持田製薬株式会社 Self-emulsifying composition of ω3 fatty acid
WO2012032414A2 (en) * 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture, a surfactant, and a statin
AR089441A1 (en) * 2011-12-22 2014-08-20 Baes Erik GELATIN / ALGINATE CAPSULES OF DELAYED LIBERATION THAT INCLUDE OMEGA-3 FATTY ACIDS AND METHODS AND USES OF THE SAME, MANUFACTURE METHOD, PHARMACEUTICAL COMPOSITION
CN104321053A (en) * 2012-03-30 2015-01-28 桑茨利奥&孔帕尼股份有限公司 Omega-3 fatty acid ester compositions

Also Published As

Publication number Publication date
MA40846A (en) 2017-09-05
CL2017000867A1 (en) 2017-11-03
EP3212236A1 (en) 2017-09-06
CA2963952C (en) 2023-10-17
MX2020002238A (en) 2020-07-13
MX2017004324A (en) 2017-07-04
WO2016057915A1 (en) 2016-04-14
BR112017007428A2 (en) 2017-12-19
CA2963952A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
IL275578A (en) Fatty acid cysteamine conjugates and their use as activators of autophagy
ZA201702385B (en) Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
HK1232160A1 (en) Fatty acids and their use in conjugation to biomolecules
PL3020401T3 (en) Pemafibrate for use in the treatment of non-alcoholic fatty liver disease
SG11201608217PA (en) Fatty acid composition and use thereof
SG11201803022TA (en) Compositions comprising fatty acids and their use
IL250271A0 (en) Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
RS59523B1 (en) Mixture of fatty acids for use in the treatment of inflammatory pathologies
EP3661600A4 (en) Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
HRP20190211T1 (en) Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
IL252992B (en) Grape products for nonalcoholic fatty liver disease and other uses
HK1210058A1 (en) Esters of short chains fatty acids for use in the treatment of immunogenic disorders
EP3206677A4 (en) Monounsaturated fatty acid compositions and use for treating atherosclerosis
EP3027180A4 (en) Compositions and methods of the treatment of fatty acid metabolism disorders
GB201516437D0 (en) Compositions and methods relating to the treatment of disease
IL243402A0 (en) Methods of identifying compositions which can be used in the treatment of heart diseases and uses of such compounds in the treatment of same
GB201317059D0 (en) Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease